A Study of LY2216684 in Participants With Major Depression Disorder
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of
LY2216684 administered once daily in the adjunctive treatment with an Selective Serotonin
Reuptake Inhibitors (SSRI) for up to approximately 1 year in participants with Major
Depressive Disorder (MDD) who were partial responders to their SSRI treatment.